August 2014 Vol. 6 Issue 81


Connecting Endocrinology and Naturopathic Medicine

by Jaclyn Chasse-Smeaton, ND  In this interview with Alan Christianson, ND, president of the Endocrine Association of Naturopathic Physicians, we discuss the organization’s locus as a collaborative forum for practitioners meeting the challenges of treating endocrine disorders with naturopathic medicine.

Treat the Patient, Not the Lab Test

by Tina Kaczor, ND, FABNO  In this interview, Michael Friedman, ND, founder and executive director of the Association for the Advancement of Restorative Medicine discusses the challenges of treating patients with thyroid and adrenal dysfunction and why he believes a collaborative response provides patients with the best care.

Abstracts & Commentary

Vitamin D Status and In-Vitro Fertilization Outcomes

by Setareh Tais, ND  In a study of 99 recipients of egg donation at the University of Southern California Fertility Center, Los Angeles, vitamin D deficiency was associated with a 50% reduction in pregnancy and live-birth rates in recipients of donor eggs compared to patients who had adequate vitamin D levels.

Antidiabetic Effects of Ginseng Extract

by Lorinda Sorensen, ND, LAc  After an 8-week intervention of ingesting 480 mg of panax ginseng twice daily, study participants demonstrated a statistically significant difference in their fasting glucose level while other glucose measures showed a slight, if not statistically significant, improvement over placebo.

Polycystic Ovarian Spectrum

by Jaclyn Chasse-Smeaton, ND  For this prospective, cohort study, 507 menstrual cycles of 259 eumenorrheic women without a self-reported history of infertility, polycystic ovarian syndrome (PCOS), or other endocrine disorders were tracked over 1 to 2 menstrual cycles. The wide-ranging results support the theory that PCOS can be redefined as polycystic ovary spectrum, with even healthy menstruating women experiencing occasional hormonal dysfunction.

Peer-Reviewed Articles

Bioidentical Hormone Replacement Therapy in Postmenopausal Osteoporosis

by Sarah Bedell Cook, ND  Osteoporosis is estimated to affect more than 10 million Americans, with postmenopausal women at particular risk. Osteoporotic fractures can lead to postural changes, emotional distress, and chronic pain. Currently all medications approved by the US Food and Drug Administration for the treatment of osteoporosis carry slight to modest risks depending on the individual, the duration, the dosage, and the drug being used. Estrogen replacement therapy is not currently indicated for the treatment of osteoporosis, but it is approved for osteoporosis prevention. Interest in bioidentical hormone replacement as an alternative to conventional hormone replacement has increased in the last 12 years, although not always for logical or scientific reasons. The purpose of this review is to bring clinicians up to date on current information on the efficacy and safety of bioidentical hormones for the prevention of postmenopausal osteoporosis.

Healthcare Perspectives

Thyroxine and Triiodothyronine in Commercially Available Thyroid Supplements?

by Tina Beaudoin, ND  A recent study from the journal Thyroid found potentially dangerous adulteration in many popular thyroid supplements. All integrative practitioners who use thyroid support dietary supplements in their practices should be concerned and should commit to asking manufacturers if any product or its component ingredients have been tested for T3 and T4 adulteration.